This biological process, where mature, specialized cells lose their distinct characteristics and revert to a more primitive, aggressive state, is a universally recognized sign of poor prognosis across ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially eliminating the need for complex lab-based manufacturing. Early results show rapid ...

With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients.

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AMLHOUSTON, ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

For years, one of the most powerful weapons against certain blood cancers, called CAR-T cell therapy, has required an elaborate process: Doctors ...

Scientists at Georgetown University's Lombardi Comprehensive Cancer Center have uncovered a new dual function for a ...

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.

Type 2 diabetes (T2D) and obesity are metabolic conditions with many causes, including overlapping and distinct genetic ...